AstraZeneca Pharma India has received a ₹148.66 crore demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging on Symbicort Turbuhaler. The company is evaluating the notice and considering legal action.
AstraZeneca Pharma India Receives ₹148.66 Crore Demand Notice from NPPA
AstraZeneca Pharma India has been issued a significant demand notice for ₹148.66 crore by the National Pharmaceutical Pricing Authority (NPPA) over allegations of overcharging. ## What just happened The NPPA has demanded ₹148.66 crore from AstraZeneca Pharma India, including interest, for alleged overcharging on the product 'Symbicort Turbuhaler 160/4.5'. The period under scrutiny is from May 2016 to November 2025. ## Why this matters This is a material financial demand that could impact the company's profitability and cash flow if the claim is upheld. It signals increased regulatory scrutiny on drug pricing in India. ## The backstory The demand notice follows a previous show-cause notice issued by the NPPA on September 11, 2025. The NPPA's action is based on alleged violations of the Drugs (Prices Control) Order, 2013 ('DPCO, 2013'). ## What changes now AstraZeneca Pharma India must pay the amount within 30 days of receiving the notice dated July 29, 2026. The company is currently evaluating the notice and exploring legal recourse, indicating they may contest the NPPA's findings. ## Risks to watch Investors should monitor the company's legal strategy, potential financial provisions, and any appeals against the NPPA's order. The final outcome will determine the financial implications. ## Peer comparison Drug pricing remains a sensitive area for pharmaceutical companies operating in India, with NPPA actively monitoring compliance with DPCO regulations across the industry. ## Context metrics (time-bound) The demand covers alleged overcharging between May 2016 and November 2025. Payment is due within 30 days of July 29, 2026. ## What to track next Keep an eye on AstraZeneca's response to the notice and any updates on their legal challenges or negotiations with the NPPA.
